Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCC-005
- Development stage
- Preclinical
- Lead developer
- Vaccentis
- Modality
- Vaccines & Immunotherapeutics
01
Overview
VCC-005 is an investigational therapeutic cancer vaccine being developed by Vaccentis for the treatment of bladder cancer. Currently in the preclinical stage of development, VCC-005 is part of a pipeline of personalized immunotherapy candidates. Although specific mechanistic details for VCC-005 have not been fully disclosed, it belongs to the same platform as Vaccentis's lead candidate VCC-001, which is an autologous tumor vaccine designed to induce a patient-specific immune response against tumor-specific antigens. The goal of VCC-005 is to prime the patient's immune system to recognize and attack bladder cancer cells based on their unique antigenic profile.
Beyond the preview
Go deeper on VCC-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCC-005.